MDGL

Madrigal Pharmaceuticals (MDGL)

About Madrigal Pharmaceuticals (MDGL)

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Details

Daily high

$560.00

Daily low

$544.24

Price at open

$554.78

52 Week High

$605.00

52 Week Low

$265.00

Market cap

12.6B

Dividend yield

0.00%

Volume

270,722

Avg. volume

304,549

P/E ratio

-42.63

Madrigal Pharmaceuticals News